Srdan Verstovsek
Department of Leukemia, The University of Texas MD Anderson Cancer Center · M.D. Anderson Cancer Center · MD Anderson Cancer Center, Houston, TX, 77030
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Srdan Verstovsek as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:55 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04173494 · A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)Sierra Oncology LLC - a GSK company · completed · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · principal investigator
- Ph2NCT02421354 · Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisM.D. Anderson Cancer Center · terminated · Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · principal investigator
- Ph2NCT02267278 · Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)M.D. Anderson Cancer Center · completed · Myeloproliferative Diseases · principal investigator
- Ph1/Ph2NCT01423851 · Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MFNS Pharma, Inc. · completed · Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis · principal investigator
- Ph2NCT01375140 · Ruxolitinib and Lenalidomide for Patients With MyelofibrosisM.D. Anderson Cancer Center · completed · Myeloproliferative Diseases · principal investigator
- Ph2NCT01371617 · A Phase 2 Study With IPI-926 in Patients With MyelofibrosisInfinity Pharmaceuticals, Inc. · completed · Primary Myelofibrosis, Fibrosis, Bone Marrow · principal investigator
- Ph2NCT01340651 · Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsIncyte Corporation · completed · Myelofibrosis · principal investigator
- Ph1/Ph2NCT01251965 · Phase l/II Study of Ruxolitinib for Acute LeukemiaM.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph3NCT01243944 · Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)Incyte Corporation · completed · Polycythemia Vera · study director
- Ph3NCT00952289 · COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialIncyte Corporation · completed · MPN (Myeloproliferative Neoplasms) · study director
- Ph2NCT00946270 · Pomalidomide for Myelofibrosis PatientsM.D. Anderson Cancer Center · completed · Polycythemia Vera, Thrombocythemia · principal investigator
- Ph2NCT00918931 · Obatoclax for Systemic MastocytosisM.D. Anderson Cancer Center · terminated · Leukemia, Systemic Mastocytosis · study chair
- Ph1NCT00910728 · Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesAstraZeneca · completed · Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis · principal investigator
- Ph1/Ph2NCT00719836 · A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesS*BIO · completed · Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia · principal investigator
- Ph2NCT00569660 · Ph II Study of Azacitidine in MyelofibrosisM.D. Anderson Cancer Center · completed · Myelofibrosis · principal investigator
- Ph1/Ph2NCT00509899 · Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisIncyte Corporation · completed · Myelofibrosis, Polycythemia Vera, Thrombocytosis · principal investigator
- Ph2NCT00494585 · CEP-701 for PH-negative MyelofibrosisM.D. Anderson Cancer Center · completed · Leukemia, Myelofibrosis · principal investigator
- Ph2NCT00493129 · Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)M.D. Anderson Cancer Center · completed · Leukemia, Systemic Mastocytosis · principal investigator
- Ph2NCT00449748 · Everolimus (RAD001) as Therapy for Patients With Systemic MastocytosisM.D. Anderson Cancer Center · completed · Systemic Mastocytosis · principal investigator
- Ph2NCT00387426 · Sunitinib in Treating Patients With Idiopathic MyelofibrosisNational Cancer Institute (NCI) · terminated · Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission · principal investigator
- Ph2NCT00352794 · Lenalidomide for Patients With Myelofibrosis (MF)M.D. Anderson Cancer Center · completed · Myelofibrosis · principal investigator
- Ph2NCT00096148 · Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaNational Cancer Institute (NCI) · terminated · Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) · principal investigator
- Ph2NCT00089388 · Cilengitide in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI) · terminated · Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAMLR01CA233457 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2024 · $452,068 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT02421354
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:55 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med · 20121,769 citationsRCR 44.2
- Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.Blood · 2006398 citationsRCR 8.1
- 312 citationsRCR 6.4
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.Lancet Haematol · 2018285 citationsRCR 9.3
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- 261 citationsRCR 5.6
- Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.Clin Cancer Res · 2006253 citationsRCR 5.1
- 226 citationsRCR 8.0
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.Haematologica · 2011176 citationsRCR 4.1
- 175 citationsRCR 4.3